In the separate comparative analyses, the results also showed no significant differences in the rate of COVID-19 hospitalization in psoriasis patients receiving any of the specific non-biologics alone compared to those receiving IL-17 inhibitors (Figure S2). The gene discussed is IL17A; the disease is COVID-19.